Related content

Long-Term Follow-Up Outcome of Imatinib Mesylate Treatment for Recurrent and Unresectable Gastrointestinal Stromal Tumors

By  

Digestion, Vol. 87, Iss. 1, 2013-01 ,pp. : 47-52

Karger

Access to resources Recommend Favorite

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors

By Sicklick Jason   Lopez Nicole  

Journal of Gastrointestinal Surgery, Vol. 17, Iss. 11, 2013-11 ,pp. : 1997-2006

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems

By Zhong Jian-Hong   Ma Liang   Li Le-Qun   Ru Hai-Ming   Zhao Yin-Nong  

Scandinavian Journal of Gastroenterology, Vol. 46, Iss. 6, 2011-06 ,pp. : 645-651

Informa Healthcare

Access to resources Recommend Favorite

Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy

By Yu Ji-Ren   Yang Xiao-Jun   Yang Wei-Li   Gao Yuan   Zhang Qing  

Scandinavian Journal of Gastroenterology, Vol. 42, Iss. 9, 2007-01 ,pp. : 1138-1140

Informa Healthcare

Access to resources Recommend Favorite

Effect of Imatinib Mesylate in a Patient with a Metastatic Gastrointestinal Stromal Tumor with a c-kit Mutation in Exon 11

By Kubota Keisuke   Katayama Atom   Takeshita Yutarou   Nozaki Koji   Ueda Tetsuya   Imamura Kazuhiro   Hiki Naoki   Nomura Sachiyo   Kaminishi Michio   Mafune Ken-Ichi  

Digestive Diseases and Sciences, Vol. 52, Iss. 7, 2007-07 ,pp. : 1725-1729

Springer Publishing Company

Access to resources Recommend Favorite